Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
2.
Int J Infect Dis ; 91: 44-49, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31740407

ABSTRACT

OBJECTIVES: We assessed the economic burden of AIDS-defining illnesses (ADIs), which was further stratified by adherence to antiretroviral therapy (ART). METHODS AND MATERIALS: A nationwide longitudinal cohort of 18,234 incident cases with HIV followed for 11years was utilized. Adherence to ART was measured by medication possession ratio (MPR). Generalized estimating equations modeling was used to estimate the cost impact of ADIs. RESULTS: Having opportunistic infections increased the annual cost by 9% (varicella-zoster virus infection) to 98% (cytomegalovirus disease), while the annual costs increased by 26% (Kaposi's sarcoma) to 95% (non-Hodgkin's lymphoma) in the year when AIDS-related cancer occurred. ADIs occurred more frequently in the years with low adherence for ART compared to the high-adherence years (e.g., 0.1≤MPR<0.8 vs. MPR≥0.8, event rate of cytomegalovirus disease 4.03% vs. 0.51%). The annual baseline costs in the years with MPR<0.1, 0.1≤MPR<0.8, and MPR≥0.8 were $250, $4,752, and $8,990 (in 2018 USD), respectively. The economic impact of ADIs in the years with low adherence (MPR<0.1) was larger than that in the high-adherence years (MPR≥0.8) (e.g., MPR<0.1 vs. MPR≥0.8, annual cost increased by 244% vs. 9% when candidiasis occurred). CONCLUSIONS: Adherence to ART may increase the baseline medical costs but mitigate the incidence and economic burden of ADIs.


Subject(s)
AIDS-Related Opportunistic Infections/economics , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/economics , Adult , Anti-HIV Agents/therapeutic use , Candidiasis/complications , Candidiasis/economics , Cost of Illness , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/economics , Female , Humans , Longitudinal Studies , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/economics , Male , Middle Aged , Sarcoma, Kaposi/complications , Sarcoma, Kaposi/economics , Varicella Zoster Virus Infection/complications , Varicella Zoster Virus Infection/economics
3.
J Med Microbiol ; 67(2): 215-227, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29244019

ABSTRACT

PURPOSE: Previous epidemiological and cost studies of fungal meningitis have largely focused on single pathogens, leading to a poor understanding of the disease in general. We studied the largest and most diverse group of fungal meningitis patients to date, over the longest follow-up period, to examine the broad impact on resource utilization within the United States. METHODOLOGY: The Truven Health Analytics MarketScan database was used to identify patients with a fungal meningitis diagnosis in the United States between 2000 and 2012. Patients with a primary diagnosis of cryptococcal, Coccidioides, Histoplasma, or Candida meningitis were included in the analysis. Data concerning healthcare resource utilization, prevalence and length of stay were collected for up to 5 years following the original diagnosis. RESULTS: Cryptococcal meningitis was the most prevalent type of fungal meningitis (70.1 % of cases over the duration of the study), followed by coccidioidomycosis (16.4 %), histoplasmosis (6.0 %) and candidiasis (7.6 %). Cryptococcal meningitis and candidiasis patients accrued the largest average charges ($103 236 and $103 803, respectively) and spent the most time in the hospital on average (70.6 and 79 days). Coccidioidomycosis and histoplasmosis patients also accrued substantial charges and time in the hospital ($82 439, 48.1 days; $78 609, 49.8 days, respectively). CONCLUSION: Our study characterizes the largest longitudinal cohort of fungal meningitis in the United States. Importantly, the health economic impact and long-term morbidity from these infections are quantified and reviewed. The healthcare resource utilization of fungal meningitis patients in the United States is substantial.


Subject(s)
Cost of Illness , Health Resources/statistics & numerical data , Meningitis, Fungal/epidemiology , Meningitis, Fungal/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Candidiasis/economics , Candidiasis/epidemiology , Candidiasis/microbiology , Coccidioidomycosis/economics , Coccidioidomycosis/epidemiology , Coccidioidomycosis/microbiology , Female , Histoplasmosis/economics , Histoplasmosis/epidemiology , Histoplasmosis/microbiology , Humans , Male , Meningitis, Cryptococcal/economics , Meningitis, Cryptococcal/epidemiology , Meningitis, Cryptococcal/microbiology , Meningitis, Fungal/diagnosis , Meningitis, Fungal/economics , Middle Aged , Prevalence , United States/epidemiology , Young Adult
4.
Am J Perinatol ; 34(1): 62-69, 2017 01.
Article in English | MEDLINE | ID: mdl-27240097

ABSTRACT

Objective Outcomes for gastroschisis (GS) remain highly variable and avoiding infectious complications (ICs) may represent a significant improvement opportunity. Our objective was to provide estimates of the impact of IC on length of stay (LOS) and costs. Study Design Using a national database, 1,378 patients with GS were identified. Patient and hospital characteristics were compared and LOS and costs evaluated for patients with and without IC. Results Two-thirds of all GS patients had IC, and IC were common for simple and complex GS (65, 73%, respectively). After controlling for patient and hospital factors, LOS in patients with IC was significantly longer than in patients without IC (4.5-day increase, p = 0.001). Specifically, sepsis was associated with increasing median LOS by 11 days (p ≤ 0.001), candida infection by 14 days (p < 0.001), and wound infection by 7 days (p = 0.007). Although overall costs did not differ between patients with and without IC, costs were elevated based on specific IC. Sepsis increased median costs by $22,380 (95% confidence interval [CI]: $14,372-30,388; p ≤ 0.001), wound infection by $32,351 (95% CI: $17,221-47,481; p ≤ 0.001), catheter-related infection by $57,180 (95% CI: $12,834-101,527; p = 0.011), and candida infections by $24,500 (95% CI: $8,832-40,167; p = 0.002). Conclusion IC among GS patients are common and contribute to increased LOS and costs. Quantifying clinical and financial ramifications of IC may help direct future quality improvement efforts.


Subject(s)
Candidiasis/epidemiology , Gastroschisis/surgery , Health Care Costs , Length of Stay/statistics & numerical data , Sepsis/epidemiology , Surgical Wound Infection/epidemiology , Candidiasis/economics , Databases, Factual , Female , Hospital Costs , Humans , Infant, Newborn , Intensive Care, Neonatal/economics , Length of Stay/economics , Male , Postoperative Complications/economics , Postoperative Complications/epidemiology , Retrospective Studies , Sepsis/economics , Surgical Wound Infection/economics
5.
J Crit Care ; 31(1): 194-200, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26586445

ABSTRACT

PURPOSE: Evidence shows that single-patient rooms can play an important role in preventing cross-transmission and reducing nosocomial infections in intensive care units (ICUs). This case study investigated whether cost savings from reductions in nosocomial infections justify the additional construction and operation costs of single-bed rooms in ICUs. MATERIALS AND METHODS: We conducted deterministic and probabilistic return-on-investment analyses of converting the space occupied by open-bay rooms to single-bed rooms in an exemplary ICU. We used the findings of a study of an actual ICU in which the association between the locations of patients in single-bed vs open-bay rooms with infection risk was evaluated. RESULTS: Despite uncertainty in the estimates of costs, infection risks, and length of stay, the cost savings from the reduction of nosocomial infections in single-bed rooms in this case substantially outweighed additional construction and operation expenses. The mean value of internal rate of return over a 5-year analysis period was 56.18% (95% credible interval, 55.34%-57.02%). CONCLUSIONS: This case study shows that although single-patient rooms are more costly to build and operate, they can result in substantial savings compared with open-bay rooms by avoiding costs associated with nosocomial infections.


Subject(s)
Cost Savings/economics , Cross Infection/economics , Intensive Care Units/economics , Models, Economic , Patients' Rooms/economics , Canada , Candidiasis/economics , Candidiasis/prevention & control , Cross Infection/prevention & control , Hospital Costs , Hospital Design and Construction/economics , Humans , Methicillin-Resistant Staphylococcus aureus , Pseudomonas Infections/economics , Pseudomonas Infections/prevention & control , Staphylococcal Infections/economics , Staphylococcal Infections/prevention & control
7.
Eur J Clin Microbiol Infect Dis ; 33(1): 7-21, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24026863

ABSTRACT

Invasive fungal diseases (IFDs) have been widely studied in recent years, largely because of the increasing population at risk. Aspergillus and Candida species remain the most common causes of IFDs, but other fungi are emerging. The early and accurate diagnosis of IFD is critical to outcome and the optimisation of treatment. Rapid diagnostic methods and new antifungal therapies have advanced disease management in recent years. Strategies for the prevention and treatment of IFDs include prophylaxis, and empirical and pre-emptive therapy. Here, we review the available primary literature on the clinical and economic burden of IFDs in Europe from 2000 to early 2011, with a focus on the value and outcomes of different approaches.


Subject(s)
Aspergillosis/economics , Aspergillosis/epidemiology , Candidiasis/economics , Candidiasis/epidemiology , Antifungal Agents/therapeutic use , Aspergillosis/diagnosis , Aspergillosis/drug therapy , Candidiasis/diagnosis , Candidiasis/drug therapy , Clinical Laboratory Techniques/methods , Early Diagnosis , Europe/epidemiology , Humans
8.
J Med Econ ; 16(11): 1344-56, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24003830

ABSTRACT

BACKGROUND: Systemic Candida infections (SCI) occur predominantly in intensive care unit patients and are a common cause of morbidity and mortality. Recently, changes in Candida epidemiology with an increasing prevalence of SCI caused by Candida non-albicans species have been reported. Resistance to fluconazole and azoles in general is not uncommon for non-albicans species. Despite guidelines recommending initial treatment with broad-spectrum antifungals such as echinocandins with subsequent switch to fluconazole if isolates are sensitive (de-escalation strategy), fluconazole is still the preferred first-line antifungal (escalation) in many clinical practice settings. After diagnosis of the pathogen, the initial therapy with fluconazole is switched to a broad-spectrum antifungal if a non-albicans is identified. METHODS: The cost-effectiveness of initial treatment with micafungin (de-escalation) vs fluconazole (escalation) in patients with SCI was estimated using decision analysis based on clinical and microbiological data from pertinent studies. The model horizon was 42 days, and was extrapolated to cover a lifetime horizon. All costs were analyzed from the UK NHS perspective. Several assumptions were taken to address uncertainties; the limitations of these assumptions are discussed in the article. RESULTS: In patients with fluconazole-resistant isolates, initial treatment with micafungin avoids 30% more deaths and successfully treats 23% more patients than initial treatment with fluconazole, with cost savings of £1621 per treated patient. In the overall SCI population, de-escalation results in 1.2% fewer deaths at a marginal cost of £740 per patient. Over a lifetime horizon, the incremental cost-effectiveness of de-escalation vs escalation was £15,522 per life-year and £25,673 per QALY. CONCLUSIONS: De-escalation from micafungin may improve clinical outcomes and overall survival, particularly among patients with fluconazole-resistant Candida strains. De-escalation from initial treatment with micafungin is a cost-effective alternative to escalation from a UK NHS perspective, with a differential cost per QALY below the 'willingness-to-pay' threshold of £30,000.


Subject(s)
Antifungal Agents/economics , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Echinocandins/economics , Echinocandins/therapeutic use , Lipopeptides/economics , Lipopeptides/therapeutic use , Antifungal Agents/administration & dosage , Candidiasis/economics , Candidiasis/mortality , Cost-Benefit Analysis , Decision Support Techniques , Echinocandins/administration & dosage , Fluconazole/economics , Fluconazole/therapeutic use , Health Services/economics , Health Services/statistics & numerical data , Humans , Life Expectancy , Lipopeptides/administration & dosage , Micafungin , Microbial Sensitivity Tests , Quality-Adjusted Life Years
9.
Farm Hosp ; 36(4): 207-15, 2012.
Article in Spanish | MEDLINE | ID: mdl-22118764

ABSTRACT

OBJECTIVE: To estimate the cost of 3 candins (anidulafungin, caspofungin and micafungin) in the treatment of adult non-neutropaenic patients with invasive candidiasis (IC) in a Spanish hospital pharmacy setting. METHODS: The overall cost impact was evaluated by varying the percentage dosage required of each candin in different possible scenarios. The prices (in euros) for each presentation were obtained from the Drug Catalogue (in August 2010). Only drug purchase costs were considered. The results are expressed as total cost for each of the 3 candins. RESULTS: The cost per episode (14 days) of anidulafungin was constant at €5400 per patient. The cost of caspofungin varied from €4281 to €7991, depending on patient weight and liver dysfunction. The cost of micafungin varied from €6000 (100mg/day) to €9000 (when increasing the dose due to inadequate response). Based on a hypothetic cohort of 100 patients with IC, the total cost of anidulafungin treatment would be €540,000, for caspofungin it would be €631,459, and for micafungin it would be €632,998, depending on any dose adjustment required. CONCLUSION: Patients treated with anidulafungin did not require dose adjustment, unlike those treated with caspofungin or micafungin. The use of anidulafungin is a cost-saving treatment for adult non-neutropaenic patients with IC, which would result in better control of the Spanish pharmacy budget.


Subject(s)
Antifungal Agents/economics , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Candidiasis/economics , Echinocandins/economics , Echinocandins/therapeutic use , Lipopeptides/economics , Lipopeptides/therapeutic use , Adult , Anidulafungin , Antifungal Agents/administration & dosage , Caspofungin , Costs and Cost Analysis , Drug Costs , Echinocandins/administration & dosage , Humans , Lipopeptides/administration & dosage , Micafungin , Pharmacy Service, Hospital/economics , Spain
10.
Mycoses ; 55(1): 27-35, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21668518

ABSTRACT

The echinocandins are antifungal agents, which act by inhibiting the synthesis of ß-(1,3)-D-glucan, an integral component of fungal cell walls. Caspofungin, the first approved echinocandin, demonstrates good in vitro and in vivo activity against a range of Candida species and is an alternative therapy for Aspergillus infections. Caspofungin provides an excellent safety profile and is therefore favoured in patients with moderately severe to severe illness, recent azole exposure and in those who are at high risk of infections due to Candida glabrata or Candida krusei. In vivo/in vitro resistance to caspofungin and breakthrough infections in patients receiving this agent have been reported for Candida and Aspergillus species. The types of pathogens and the frequency causing breakthrough mycoses are not well delineated. Caspofungin resistance resulting in clinical failure has been linked to mutations in the Fksp subunit of glucan synthase complex. European Committee for Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute need to improve the in vitro susceptibility testing methods to detect fks hot spot mutants. Caspofungin represents a significant advance in the care of patients with serious fungal infections.


Subject(s)
Aspergillus/drug effects , Biofilms , Candida/drug effects , Echinocandins/therapeutic use , Antifungal Agents/metabolism , Antifungal Agents/pharmacokinetics , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/economics , Aspergillosis/microbiology , Aspergillus/metabolism , Aspergillus/physiology , Candida/metabolism , Candida/physiology , Candidiasis/drug therapy , Candidiasis/economics , Candidiasis/microbiology , Caspofungin , Cell Wall/drug effects , Cell Wall/metabolism , Clinical Trials as Topic , Drug Resistance, Fungal , Echinocandins/metabolism , Echinocandins/pharmacokinetics , Glucosyltransferases/metabolism , Guidelines as Topic , Humans , Lipopeptides , Proteoglycans , beta-Glucans/metabolism
11.
Virulence ; 1(5): 367-75, 2010.
Article in English | MEDLINE | ID: mdl-21178472

ABSTRACT

BACKGROUND: Data on Candida infection among critically ill trauma patients are limited and not recently updated. Here we study the epidemiology and economic impact of Candida and examine potential risk factors for Candida infection in this population. METHODS: In this 5-year retrospective study, all severely injured patients with ≥4 days of intensive care unit stay were included, with the primary outcome being Candida infection. We identified 3 distinct patient groups: 1) The Candida infection, 2) The Candida colonization and 3) the Candida-free group. All comparisons between groups with p-values ≤0.2 from the univariate analysis were entered into stepwise logistic regression to identify independent risk factors for candidiasis. RESULTS: 374 patients were included. Upon comparisons between groups, candidiasis patients received significantly more blood transfusions (p=0.013), antibiotics (p=0.005), and total parenteral nutrition (TPN) (p=0.004), had a longer duration of mechanical ventilation (MV) (p=0.008) and underwent more laparotomy procedures than Candida free patients (56.5% versus 16.4%; p<0.001). Surgical complications (13% versus 1.4%; p=0.013), injury of the upper (13% versus 0.9%; p=0.007) and lower gastrointestinal tract (8.7% versus 0.9%; p=0.048), and bacterial wound or intra-abdominal infections (17.4% versus 1.9%; p=0.004) were also more common in candidiasis patients. Upon multivariate analysis, patients receiving TPN had 7-fold higher odds for developing candidiasis (Odds ratio [OR]: 7.2; 95% Confidence interval [CI]: 2.6-19.4; p=0.0001). Other predisposing factors included laparotomy (OR: 3.8, 95% CI: 1.5-9.9; p=0.0057) and female gender (OR: 5.7; 95% CI: 2.1-15.6; p=0.0007). Average total hospital charges were higher for patients with Candida infection compared to patients with Candida colonization or without a positive Candida culture. CONCLUSIONS: TPN, laparotomy, and female gender independently predict the development of candidiasis among trauma patients. Severely injured women requiring laparotomy and TPN therapy should be carefully managed for the possibility of increased risk for candidiasis.


Subject(s)
Candida/isolation & purification , Candidiasis/epidemiology , Carrier State/epidemiology , Wounds and Injuries/complications , Adult , Aged , Candidiasis/economics , Candidiasis/microbiology , Carrier State/economics , Carrier State/microbiology , Critical Illness , Female , Humans , Laparotomy/adverse effects , Male , Middle Aged , Parenteral Nutrition/adverse effects , Retrospective Studies , Risk Factors , Sex Factors
12.
Am J Infect Control ; 38(9): 740-5, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20542354

ABSTRACT

BACKGROUND: The impact of reduced fluconazole susceptibility on clinical and economic outcomes in patients with Candida glabrata bloodstream infections (BSI) is unknown. METHODS: A retrospective cohort study was conducted to evaluate 30-day inpatient mortality and postculture hospital charges in patients with C glabrata BSI with decreased fluconazole susceptibility (minimum inhibitory concentration [MIC] ≥ 16 µg/mL) versus fluconazole-susceptible C glabrata BSI (MIC ≤ 8 µg/mL). These analyses were adjusted for demographics, comorbidities, and time at risk. Secondary analyses limited the C glabrata group with decreased fluconazole susceptibility to MIC ≥ 64 µg/mL. RESULTS: There were 45 (31%) deaths among 144 enrolled patients: 19 deaths (25%) among 76 patients with C glabrata BSI with decreased fluconazole susceptibility and 26 deaths (38%) among 68 patients with fluconazole-susceptible C glabrata BSI. Decreased fluconazole susceptibility was not independently associated with increased 30-day inpatient mortality (adjusted odds ratio, .60; 95% confidence interval (CI): .26-1.35; P = 0.22) or hospital charges (multiplicative change in hospital charges, .93; 95% CI: .60-1.43; P = 0.73). Older age was associated with increased mortality and increased time at risk was associated with increased hospital charges. CONCLUSION: Crude mortality rates remain high in patients with C glabrata BSI. However, decreased fluconazole susceptibility was not associated with increased mortality or hospital charges.


Subject(s)
Antifungal Agents/pharmacology , Candida glabrata/drug effects , Candidiasis/microbiology , Drug Resistance, Fungal , Fluconazole/pharmacology , Fungemia/microbiology , Adult , Aged , Aged, 80 and over , Candida glabrata/isolation & purification , Candidiasis/drug therapy , Candidiasis/economics , Candidiasis/mortality , Cohort Studies , Female , Fungemia/drug therapy , Fungemia/economics , Fungemia/mortality , Health Care Costs , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Treatment Outcome
13.
Pharmacotherapy ; 30(4): 361-8, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20334456

ABSTRACT

STUDY OBJECTIVES: To evaluate the impact of inappropriate therapy--defined as delayed antifungal therapy beyond 24 hours from culture collection, inadequate antifungal dosage, or administration of an antifungal to which an isolate was considered resistant--on postculture hospital length of stay and costs, and to evaluate the relationship between modifiable risk factors, including failure to remove a central venous catheter, antifungal delay, and inadequate dosage, for an additive effect on hospital length of stay and costs. DESIGN: Single-center retrospective cohort study. SETTING: 1250-bed academic medical center. PATIENTS: One hundred sixty-seven consecutive adult patients admitted between January 2004 and May 2006 with culture-confirmed Candida bloodstream infections that occurred within 14 days of hospital admission and who received at least one dose of antifungal treatment. MEASUREMENTS AND MAIN RESULTS: Patients were stratified according to appropriateness of antifungal therapy. Appropriate therapy was defined as initiation of an antifungal to which the isolated pathogen was sensitive in vitro within 24 hours of positive culture collection, in addition to receipt of an adequate dose as recommended by the Infectious Diseases Society of America and the antifungal package insert. Postculture length of stay was the primary outcome and hospital costs the secondary outcome. An evaluation of modifiable risk factors was performed separately. Data were analyzed for 167 patients (22 in the appropriate therapy group and 145 in the inappropriate therapy group). Postculture length of stay was shorter in the appropriate therapy group (mean 7 vs 10.4 days, p=0.037). This correlated with total hospital costs that were lower in the appropriate therapy group (mean $15,832 vs $33,021, p<0.001.) A graded increase in costs was noted with increasing number of modifiable risk factors (p=0.001). CONCLUSION: Inappropriate therapy for Candida bloodstream infection occurring within 14 days of hospitalization was associated with prolonged postculture length of stay and increased costs. A rise in costs, but not length of stay, was noted with increasing modifiable risk factors.


Subject(s)
Antifungal Agents/therapeutic use , Candida/drug effects , Candidiasis/drug therapy , Catheterization, Central Venous/adverse effects , Hospitalization/economics , Adult , Antifungal Agents/economics , Candidiasis/economics , Candidiasis/etiology , Catheterization, Central Venous/economics , Cohort Studies , Costs and Cost Analysis/economics , Hospital Costs , Humans , Retrospective Studies , Risk Factors
14.
Am J Infect Control ; 38(1): 78-80, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19836856

ABSTRACT

We compared costs, length of stay, and mortality between adults with Candida albicans and Candida glabrata bloodstream infections. Early evidence of C glabrata, as defined by a positive culture within 2 days of admission, was associated with higher costs ($56,026 vs $32,810; P = .04) and longer hospital stays (19.7 vs 14.5 days; P = .05) compared with early evidence of C albicans. Mortality was similar between the groups.


Subject(s)
Candida albicans/isolation & purification , Candida glabrata/isolation & purification , Candidiasis/economics , Candidiasis/mortality , Fungemia/economics , Fungemia/mortality , Length of Stay/statistics & numerical data , Adult , Aged , Aged, 80 and over , Candidiasis/microbiology , Candidiasis/pathology , Cross Infection/economics , Cross Infection/microbiology , Cross Infection/mortality , Cross Infection/pathology , Female , Fungemia/microbiology , Fungemia/pathology , Humans , Male , Middle Aged , Young Adult
15.
J Infect ; 59(5): 360-5, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19744519

ABSTRACT

BACKGROUND: There were 1967 reports of Candida species isolated from blood specimens in 2007 in the UK (excluding Scotland). Such infections are particularly common in the intensive care unit (ICU). The impact of candidaemia on mortality, length of stay (LOS) and cost in a UK hospital was examined. METHODS: A retrospective analysis of candidaemia episodes and appropriate matched controls was undertaken based on data from the ICU, high dependency units and hospital wards at Wythenshawe Hospital in Manchester. The study covered the period November 2003-February 2007. RESULTS: In total, 48 case-patients of candidaemia and 81 control-patients were identified. The attributable mortality due to candidaemia varied from 21.5% to 34.7%. Candidaemia patients spend on average 5.6 days more in the ICU than matched patients and generate mean additional costs of at least 8252 UK pounds per patient, 16,595 pounds in adults only. CONCLUSION: Candidaemia remains a severe disease associated with high attributable mortality in the UK. In addition, candidaemia leads to additional ICU length of stay and costs. The implication is an attributable cost of at least 16.2 million UK pounds with 683 deaths attributable to candidaemia per year in the UK.


Subject(s)
Candidiasis/economics , Candidiasis/mortality , Fungemia/economics , Fungemia/mortality , Length of Stay/statistics & numerical data , Adolescent , Adult , Aged , Candida albicans/isolation & purification , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Intensive Care Units , Male , Middle Aged , Retrospective Studies , United Kingdom , Young Adult
16.
Rev Iberoam Micol ; 26(1): 90-3, 2009 Mar 31.
Article in Spanish | MEDLINE | ID: mdl-19463285

ABSTRACT

BACKGROUND: Invasive candidiasis episodes have increased during last years and they have been related with high rates of crude mortality. Invasive candidiasis-related deaths have not diminished significantly with the introduction of antifungals in the past decade. Finantial managers are worried about extra costs from acquisition of new antifungal agents. AIM: This review includes the main studies age-stratified to assess different variables related to the economic burden of invasive candidiasis. METHODS: Systematic review of biomedic databases including Medline, PubMed and EMBASE. RESULTS: The studies show hospital stay as the main variable related with higher impact in the increase of invasive candidiasis costs. Acquisition costs of antifungals have a very low impact in the invasive candidiasis costs. CONCLUSIONS: Pharmacoeconomics applied in candidiasis invasive therapy must avoid assessing acquisition costs of antifungals exclusively, needing to include both direct and indirect costs associated with this fungal infection. The cost of antifungal acquisition represents a low impact in the overall economic burden of this fungal infection. Further pharmacoeconomics evaluations should be performed including similar definitions to decrease the possible bias in results interpretation.


Subject(s)
Antifungal Agents/economics , Candidiasis/drug therapy , Fungemia/drug therapy , Adult , Age Factors , Antifungal Agents/therapeutic use , Candidiasis/economics , Child , Cross Infection/drug therapy , Cross Infection/economics , Drug Costs , Financing, Government/statistics & numerical data , Financing, Personal/statistics & numerical data , Fungemia/economics , Hospital Costs , Hospitalization/economics , Humans , Infant, Low Birth Weight , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/drug therapy , Infant, Premature, Diseases/economics , Length of Stay/economics , Prospective Studies , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/economics , Retrospective Studies
17.
Pediatr Infect Dis J ; 28(5): 433-5, 2009 May.
Article in English | MEDLINE | ID: mdl-19319021

ABSTRACT

We compared length of stay, inpatient costs, and mortality associated with Candida albicans and non-albicans bloodstream infections in adults and children. Compared with adults, children with Candida bloodstream infections had longer lengths of stay (36.7 vs. 20.7 days; P < 0.001) and higher inpatient costs ($133,871 vs. $56,725; P < 0.001) but lower mortality (28.3% vs. 43.5%; P < 0.001).


Subject(s)
Candida/isolation & purification , Candidiasis/microbiology , Candidiasis/mortality , Fungemia/microbiology , Fungemia/mortality , Adolescent , Adult , Candidiasis/economics , Child , Child, Preschool , Cohort Studies , Fungemia/economics , Health Care Costs , Hospitalization/economics , Humans , Infant , Length of Stay/economics , Young Adult
18.
Rev. iberoam. micol ; 26(1): 90-93, mar. 2009. tab
Article in Spanish | IBECS | ID: ibc-136112

ABSTRACT

Antecedentes: Con los años, los episodios de candidiasis invasora se han incrementado y se han asociado con ratios elevados de mortalidad bruta. Los antifúngicos introducidos durante la pasada década no han producido una disminución significativa de la mortalidad relacionada con esta enfermedad infecciosa. Los costes de adquisición de los antifúngicos suponen una gran preocupación en la gestión de los costes de farmacia. Objetivos: Desarrollar una revisión de los principales estudios efectuados, estratificados por grupos de edad, para evaluar las distintas variables que afectan a la carga económica, así como los costes ocasionados por la candidiasis invasora. Métodos: Búsqueda sistemática de bases de datos Medline, PubMed y EMBASE. Resultados: Los estudios efectuados en pacientes con candidiasis invasora muestran que la estancia hospitalaria es la variable con más impacto en el incremento de los costes relacionados con esta infección fúngica. El coste de adquisición de los antifúngicos representa un porcentaje muy inferior al de otras variables analizadas. Conclusiones: El análisis farmacoeconómico de la candidiasis invasora requiere la inclusión del estudio de los costes directos e indirectos que lleva asociados, y no tan sólo, el de los costes de adquisición de los antifúngicos. Estos últimos representan una pequeña parte del coste total de esta enfermedad. Es preciso efectuar nuevos análisis farmacoeconómicos que unifiquen las definiciones utilizadas en los estudios con el fin de disminuir su impacto en la interpretación de los resultados (AU)


Background: Invasive candidiasis episodes have increased during last years and they have been related with high rates of crude mortality. Invasive candidiasis-related deaths have not diminished significantly with the introduction of antifungals in the past decade. Finantial managers are worried about extra costs from acquisition of new antifungal agents. Aim: This review includes the main studies agestratified to assess different variables related to the economic burden of invasive candidiasis. Methods: Systematic review of biomedic databases including Medline, PubMed and EMBASE. Results: The studies show hospital stay as the main variable related with higher impact in the increase of invasive candidiasis costs. Acquisition costs of antifungals have a very low impact in the invasive candidiasis costs. Conclusions: Pharmacoeconomics applied in candidiasis invasive therapy must avoid assessing acquisition costs of antifungals exclusively, needing to include both direct and indirect costs associated with this fungal infection. The cost of antifungal acquisition represents a low impact in the overall economic burden of this fungal infection. Further pharmacoeconomics evaluations should be performed including similar definitions to decrease the possible bias in results interpretation (AU)


Subject(s)
Humans , Infant, Newborn , Adult , Antifungal Agents/economics , Candidiasis/drug therapy , Fungemia/drug therapy , Fungemia/economics , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/economics , Infant, Premature , Infant, Premature, Diseases/drug therapy , Infant, Premature, Diseases/economics , Infant, Low Birth Weight , Age Factors , Antifungal Agents/therapeutic use , Candidiasis/economics , Drug Costs , Financing, Government/statistics & numerical data , Financing, Personal/statistics & numerical data , Hospital Costs , Hospitalization/economics , Retrospective Studies , Prospective Studies , Length of Stay/economics
19.
Eur J Clin Microbiol Infect Dis ; 28(6): 689-92, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19011913

ABSTRACT

Candida bloodstream infection (CBSI) accounted for 50% of bloodstream infections in our medical intensive care unit (MICU) in 2004. Our objective was to evaluate a risk-based fluconazole prophylaxis program. CBSI incidence, patient demographics, and unit metrics were retrospectively reviewed for 2004. Starting on January 2005, patients meeting pre-specified criteria were placed on risk-based fluconazole prophylaxis and their outcomes, adverse events, and unit metrics were prospectively collected. The inclusion criteria were based on a clinical prediction rule and included an MICU stay greater than 72 h, broad-spectrum antibiotics, and central venous catheter, along with at least two of the following: mechanical ventilation for at least 48 h, any type of dialysis, parenteral nutrition, pancreatitis, systemic steroids, or other systemic immunosuppressive agents. For 2004, the unit had nine CBSI, corresponding to a rate of 3.4 CBSI/1,000 line-days. Four cases were caused by C. albicans, four by C. glabrata, and one by C. tropicalis. The mean +/- standard deviation (SD) APACHE II score for these patients was 25 +/- 9. In 2005, a total of 36 patients (2.6% of all unit admissions) received prophylaxis and the unit had two CBSI, corresponding to a rate of 0.79 CBSI/1,000 line-days. One patient had C. albicans and the other had C. tropicalis. The mean +/- SD APACHE II score for these patients was 21 +/- 8. The mean +/- SD duration of fluconazole prophylaxis was 8 +/- 6 days. Fluconazole was discontinued in two patients due to non-severe adverse events (acute eosinophilia, elevated transaminases). The attributable cost of CBSI in the unit in 2004 was $63,000 per episode. The total cost for the 36 courses of fluconazole was $6,000. When comparing the 2004 CBSI patients and the 2005 prophylaxis patients, we found similar acuity, demographics, and risk factors, with no differences in MICU or hospital mortality or length of stay. Risk-based fluconazole prophylaxis in an MICU with a high incidence of CBSI was safe and cost-effective when applied to a limited number of patients and produced a significant decrease in the incidence of this disease.


Subject(s)
Antifungal Agents/therapeutic use , Candidiasis/prevention & control , Chemoprevention/methods , Dialysis/adverse effects , Fluconazole/therapeutic use , Fungemia/prevention & control , Adult , Animals , Antifungal Agents/adverse effects , Candidiasis/economics , Fluconazole/adverse effects , Fungemia/economics , Health Care Costs , Humans , Intensive Care Units , Middle Aged , Treatment Outcome
20.
Curr Med Res Opin ; 24(1): 167-74, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18036287

ABSTRACT

OBJECTIVE: Assess the impact of esophageal candidiasis on US hospital inpatient charges, length of stay (LOS), and costs across clinically relevant subgroups. METHODS: Total hospital charge (THC) and LOS data extracted from the 2005 National Inpatient Sample (NIS) were compared for patients with and without esophageal candidiasis within the top 20 most commonly assigned Diagnosis Related Groups (DRGs) for the disease. Total hospital costs were estimated using hospital charges in the 2005 Medicare Provider Analysis and Review (MEDPAR) file and hospital cost-to-charge ratios published in the Center for Medicare and Medicaid Service's (CMS) 2005 Inpatient Prospective Payment System Standardization File. RESULTS: Across 274 DRGs, 45 727 esophageal candidiasis patients were identified. Mean age was 50.8 years; 52.5% were female, 59.3% Caucasian. Median LOS was 7 days; median THC was $25 649. Of all esophageal candidiasis cases identified, 65% fell into the top 20 most commonly assigned DRGs. Within this subset, HIV-related DRGs accounted for 22% of the esophageal candidiasis cases. The difference in mean THC and LOS for esophageal candidiasis patients in HIV-related DRGs was not significant. However, total hospital costs were higher for esophageal candidiasis patients in this subset ($11 886 vs. $10 534, p < 0.01). The remaining 78% of esophageal candidiasis cases were assigned to 19 non-HIV-related DRGs. Mean LOS, THC, and total hospital costs were significantly higher for esophageal candidiasis patients within these 19 non-HIV-related DRGs, (8.4 vs. 6.1; $35 704 vs. $23 874, and $10 917 vs. $7474, p < 0.01 in all cases). CONCLUSIONS: Esophageal candidiasis affects a wide range of patient groups; it increases LOS and total charges within non-HIV-related hospitalizations. Although the costs presented in this study are estimates, they do suggest a significant increase in cost among esophageal candidiasis cases. Future studies on treatment and preventive care strategies for esophageal candidiasis should not be limited to HIV patients, but instead performed across a wider range of disease settings.


Subject(s)
Candidiasis/economics , Diagnosis-Related Groups , Esophageal Diseases/economics , Hospital Charges , AIDS-Related Opportunistic Infections/economics , Adolescent , Adult , Aged , Aged, 80 and over , Diagnosis-Related Groups/classification , Diagnosis-Related Groups/economics , Female , Health Care Costs , Humans , Length of Stay , Male , Middle Aged , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...